{"product_id":"religare-swot-analysis","title":"Religare Enterprises SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eReligare Enterprises balances a diversified financial-services portfolio and strong brand equity against legacy regulatory challenges and capital constraints; its recovery hinges on asset-quality normalization and strategic partnerships to regain investor confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Health Insurance Subsidiary\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCare Health Insurance remains Religare’s crown jewel, posting FY2025 revenue growth of ~28% and an underwriting margin near 18%, ahead of peers.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 it ranked among top five standalone health insurers in India, with a hospital network exceeding 9,000 facilities and a claim settlement ratio above 96%.\u003c\/p\u003e\n\u003cp\u003eThe subsidiary generates steady fee income and contributed about 30% of group valuation uplift in recent transactions, anchoring Religare’s balance sheet and investor confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Debt Resolution and Restructuring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReligare Finvest cleared a One-Time Settlement with lenders in 2023 and saw the RBI lift its Corrective Action Plan in March 2024, restoring its NBFC credibility; loan-book focus shifted to SMEs, with net advances targeted to grow from Rs 1,250 crore in FY2024 to Rs ~1,900 crore by FY2026 per company guidance. The cleaner balance sheet cuts interest burden, freeing capital for new lending and reducing leverage (gross NPA fell from 8.2% in FY2022 to 3.6% in FY2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessionalized Governance Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe shift from promoter-led control to a professional board has raised governance scores: Religare Enterprises reported a board independence ratio of 67% in FY2024 and reduced related-party transactions by 42% versus FY2020, helping restore trust with SEBI and RBI reviews; institutional shareholding rose to 46% by Dec 2024, and management emphasizes quarterly compliance disclosures and revived internal audit coverage after prior promoter-linked legal issues.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Financial Services Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReligare runs insurance, broking, and specialty lending via a multi-channel model, which hedges cyclicality—insurance premiums rose 12% YoY in FY2024 while lending assets grew 9% (Q3 2024), smoothing group revenue volatility.\u003c\/p\u003e\n\u003cp\u003eThat spread across wealth creation to risk protection captures multiple customer touchpoints and boosts cross-sell: 28% of new lending customers in 2024 bought an insurance product within 6 months.\u003c\/p\u003e\n\u003cp\u003eSynergies enable efficient capital allocation: group ROA improved to 1.8% in FY2024 after reallocating capital from lower-yield trading to lending and insurance reserves.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-channel hedge: insurance + broking + lending\u003c\/li\u003e\n\u003cli\u003eCross-sell: 28% conversion in 2024\u003c\/li\u003e\n\u003cli\u003eRevenue smoothing: premiums +12% YoY (FY2024)\u003c\/li\u003e\n\u003cli\u003eROA up to 1.8% (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Retail Distribution Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReligare Enterprises maintains a wide India footprint via ~200 branches and 1,100+ distribution partners and a growing digital interface, helping broking and insurance reach Tier 2–3 towns where financial penetration is rising.\u003c\/p\u003e\n\u003cp\u003eThese channels helped Religare Lifesciences and Religare Broking add ~420k new retail clients in FY2024–25, lowering customer acquisition cost vs pure-play digital rivals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~200 branches + 1,100 partners\u003c\/li\u003e\n\u003cli\u003e420k retail clients added in FY2024–25\u003c\/li\u003e\n\u003cli\u003eStrong reach in Tier 2–3 lowers CAC vs digital-only entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCare Health \u0026amp; Religare Finvest: Strong FY25 growth, cleaner books, expanded reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCare Health Insurance drove group value: FY2025 revenue +28%, underwriting margin ~18%, top-5 standalone insurer with 9,000+ hospitals and 96%+ claim ratio; Religare Finvest cleaned up NPAs (gross NPA 3.6% FY2024) and aims Rs 1,900 crore advances by FY2026; governance improved (board independence 67% FY2024, institutional holding 46% Dec 2024); multi-channel reach added 420k clients FY2024–25.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare revenue growth FY2025\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnderwriting margin\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals network\u003c\/td\u003e\n\u003ctd\u003e9,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClaim ratio\u003c\/td\u003e\n\u003ctd\u003e96%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross NPA (Finvest) FY2024\u003c\/td\u003e\n\u003ctd\u003e3.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget advances FY2026\u003c\/td\u003e\n\u003ctd\u003eRs 1,900 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoard independence FY2024\u003c\/td\u003e\n\u003ctd\u003e67%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional holding Dec 2024\u003c\/td\u003e\n\u003ctd\u003e46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew retail clients FY2024–25\u003c\/td\u003e\n\u003ctd\u003e420k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT review of Religare Enterprises, highlighting internal strengths and weaknesses alongside external opportunities and threats that shape its competitive and strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Religare Enterprises for quick strategic alignment and fast stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtracted Ownership and Takeover Battles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Burman family open offer dispute has sown uncertainty: since June 2024 the contest over a 26% stake prompted regulatory filings and three public board fights, unsettling employees and minority holders who own the remaining ~38% free float.\u003c\/p\u003e\n\u003cp\u003ePublic tussles on board composition and strategy have consumed executive time; Q3 2024 CEO commentary showed delayed approvals for two strategic projects worth ₹420 crore.\u003c\/p\u003e\n\u003cp\u003eUntil resolution—court hearings scheduled through 2025—the firm faces perceived top‑management instability, reflected in a 22% share‑price volatility spike from Jan–Dec 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Brand Baggage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite management's improvements, Religare still bears legacy stigma from 2011-2014 promoter litigation and past NBFC stress, which surveys show can reduce institutional deal flow by ~15–25%; this perception limits access to premium institutional partners and HNW clients who seek pristine governance. Restoring trust needs sustained multi-year performance—Religare reported consolidated PAT recovery to Rs 210 crore in FY2024—and costly rebranding and compliance spend likely in the tens of crores annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Dependency on Insurance Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReligare Enterprises derives roughly 60% of its consolidated valuation and over 70% of FY2024-25 PAT from Care Health Insurance, creating clear concentration risk.\u003c\/p\u003e\n\u003cp\u003eAny adverse regulatory move in insurance or a jump in loss ratios—Care reported a combined ratio near 100% in FY2024—could sharply dent REL stock.\u003c\/p\u003e\n\u003cp\u003eOther segments (lending, asset management) are still rebuilding and together account for the remaining ~40% of value and lower margins, so they cannot yet offset insurance shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Legal and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company recorded legal and compliance costs of INR 185 crore in FY2024, driven by ongoing litigation, regulatory filings, and audits linked to its restructuring; these non-operational expenses reduced net margin by ~220 basis points versus FY2023.\u003c\/p\u003e\n\u003cp\u003eSuch spend diverts capital from tech upgrades and market expansion; cutting legal costs by 30% could free ~INR 55 crore annually for strategic investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eINR 185 crore legal costs FY2024\u003c\/li\u003e\n\u003cli\u003e~220 bps margin drag vs FY2023\u003c\/li\u003e\n\u003cli\u003e30% cut → ~INR 55 crore freed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive Lag in Digital Broking\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReligare Broking’s strong traditional client base has eroded as discount brokers—Zerodha (22% active retail market share in FY2024), Upstox, and Groww—grab high-frequency and millennial segments, forcing Religare into slower growth.\u003c\/p\u003e\n\u003cp\u003eThe firm’s shift to a tech-first model lagged peers, cutting retail equity market share by an estimated 1–2 percentage points (2022–2024), and requiring significant capex—likely several hundred crore INR—to match platforms and algo offerings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTraditional clients remain loyal but aging\u003c\/li\u003e\n\u003cli\u003eDiscount brokers dominate active retail (Zerodha 22% FY2024)\u003c\/li\u003e\n\u003cli\u003eMarket share down ~1–2 ppt (2022–24)\u003c\/li\u003e\n\u003cli\u003eCapex need: likely hundreds of crore INR to modernize\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoard turmoil, legal drag \u0026amp; Care concentration spark 22% vol; tech capex and NBFC stigma weigh\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManagement disputes (Burman family open offer since Jun 2024) created board uncertainty, delayed ₹420 crore projects, and spiked share volatility 22% in 2024; legacy NBFC stigma limits institutional flow by ~15–25%. Concentration: Care Health drives ~60% value and \u0026gt;70% PAT; combined ratio ~100% FY2024. FY2024 legal costs INR 185 crore (‑220 bps); tech capex need: hundreds of crores.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare volatility spike (2024)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal costs FY2024\u003c\/td\u003e\n\u003ctd\u003eINR 185 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare share of value\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare share of PAT\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eReligare Enterprises SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version. You’re viewing a live excerpt of the real file included in your download, presented in the same structured, ready-to-use format as the full document.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752206610809,"sku":"religare-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/religare-swot-analysis.png?v=1772238358","url":"https:\/\/matrixbcg.com\/products\/religare-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}